[Molecular markers of endothelial damage in patients with Parkinson's disease]

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(3):61-4.
[Article in Russian]

Abstract

A comparative analysis of clinical, instrumental and laboratory data in groups of patients with Parkinson's disease and chronic brain ischemia (stages I-II) was carried out. The information obtained in the groups showed significant differences in clinical and instrumental data that indicated the presence of chronic brain ischemia. A significant increase in molecular markers of endothelial damage comparable with the group of chronic cerebral ischemia was identified in patients with Parkinson's disease. The increase in indicators including monocyte chemoattractant protein-1, vascular endothelial growth factor and endothelin-1 is important for the verification of the disease before the appearance of symptoms of chronic cerebral ischemia in the examined groups of patients.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism*
  • Brain Ischemia / etiology
  • Brain Ischemia / metabolism*
  • Brain Ischemia / physiopathology
  • Chemokine CCL2 / metabolism
  • Disease Progression
  • Endothelin-1 / metabolism
  • Endothelium, Vascular / metabolism*
  • Endothelium, Vascular / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / metabolism*
  • Parkinson Disease / physiopathology
  • Prognosis
  • Severity of Illness Index
  • Vascular Endothelial Growth Factor A / metabolism
  • Vasoconstriction / physiology*

Substances

  • Biomarkers
  • Chemokine CCL2
  • Endothelin-1
  • Vascular Endothelial Growth Factor A